

**Date:** October 25, 2024

**Ref. No.:** KDL/SE/101/2024-25

<b>To,</b> <b>BSE Limited</b> <b>Corporate Relationship Department</b> 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 <b>Scrip Code:</b> 543328	<b>To,</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 <b>NSE Symbol:</b> KRSNAA
--	--

Dear Sir/Madam,

**Sub: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2024.

For Krsnaa Diagnostics Limited



**Sujoy Sudipta Bose**  
**Company Secretary & Compliance Officer**  
Encl: as above

**Krsnaa Diagnostics Ltd.**

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,  
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)  
020 27402400 | info@krsnaa.in



## Exceptional Growth with 48% EBITDA and 49% PAT Increase YoY, Enhanced by Operational Efficiencies & Strategic Alliances for Future Success

**Pune, October 25, 2024:** Krsnaa Diagnostics Ltd. ([BSE: 543328](#) | [NSE: KRSNAA](#)) is one of India's fastest growing diagnostic service providers, both in radiology and pathology. The Company today announced the results for the quarter ending September 30<sup>th</sup>, 2024.

### Financial Performance Q2 FY2025:

(Rs. Million)	Q2FY25	Q2FY24	Y-o-Y Growth	Q1FY25	Q-o-Q Growth	H1FY25	H1FY24	Y-o-Y Growth
Revenue from Operations	1,863	1,555	20%	1,702	10%	3,566	2,950	21%
Other Income	46	42		73		119	84	
Total Income	1,909	1,597		1,775		3,685	3,034	
EBITDA <sup>1</sup>	509	323	58%	442	15%	951	641	48%
Margin %	27%	21%		26%		27%	22%	
EBIT <sup>1</sup>	318	165	93%	285	12%	603	363	66%
Margin %	17%	10%		16%		17%	12%	
Profit After Tax	196	105	87%	179	9%	375	251	49%
Margin %	11%	7%		11%		11%	9%	
Reported Diluted EPS	5.92	3.23		5.46		11.38	7.73	

Notes:

1. EBITDA excludes CSR and ESOP and EBIT includes Other Income

### Operational Highlights for Q2 FY25:

- Krsnaa has won the contract for radiology and pathology at two hospitals in the city of Ranchi, Jharkhand
- Krsnaa has made a strategic investment of 23.53% stake in Apulki Healthcare Limited
- Krsnaa has established a strategic partnership with United Imaging and Medikaa Bazaar for a ₹300+ Crore investment, targeting towards the establishment of over 30+ imaging centres across India
- Krsnaa expanded its presence by establishing 871 new centers across the nation.

Commenting on the results, **Mr. Yash Mutha, Joint Managing Director**, said:

“We are pleased to report another strong quarter, with significant margin improvements highlighting the success of our operational efficiency initiatives. Additionally, we are excited to introduce new strategic initiatives aimed at expanding our footprint and enhancing service delivery. A key highlight is our entry into Jharkhand, marking a significant milestone in our mission to bring quality diagnostic services to underserved regions. This expansion is part of our broader commitment to providing accessible, affordable, and accurate diagnostics to both urban and rural populations across the country.

Our recently announced partnership with Apulki and United Imaging positions us to accelerate growth, expand our market presence, and introducing cutting edge technologies and create new value for our shareholders. We

remain focused on executing our long-term strategy of delivering sustainable, profitable growth by leveraging core strengths, optimizing cost structures, and investing in high-growth opportunities.

In the first half of FY2025, Krsnaa achieved remarkable year-on-year growth of 21%, driving total revenues to Rs. 3,566 million. The growing awareness of Krsnaa's outstanding service offerings, underpinned by competitive pricing, has significantly contributed to increased patient volumes and test counts.

On the financial front, our EBITDA reached Rs. 951 million, with margins of 27% with an impressive 48% Y-O-Y growth. Net profit stood at Rs. 375 million, with net margins of 11% with an impressive 49% Y-O-Y growth. These improvements in profitability reflect our ongoing focus on enhancing operational efficiencies through various strategic and operational initiatives. We expect to maintain this positive trajectory in margin performance over the coming quarters.

Our senior management remains deeply committed to executing our core growth strategies, and we are confident in our ability to meet our annual revenue and profitability targets. The future holds immense potential, and we are actively participating in more tenders while building a strong pipeline for continued growth and success.”

Commenting on the Business, **Ms. Pallavi Bhatevara, Executive Director, said:**

“Krsnaa Diagnostics Limited has been a key player in delivering high-quality and affordable diagnostic services, essential for disease diagnosis, management, and prevention. The provision of these services is a fundamental pillar of the healthcare industry.

In a landmark initiative poised to transform the diagnostics landscape in India, Krsnaa Diagnostics Limited, the country's largest and fastest-growing provider of diagnostic services, has entered into a strategic partnership with Medikabazaar, India's leading B2B healthcare procurement and supply chain solutions provider, and United Imaging, a global leader in advanced imaging technologies. This collaboration aims to disrupt the industry by introducing cutting-edge radiology equipment to our centers, enabling us to offer superior diagnostic imaging services.

Our strategic investment in Apulki Healthcare Private Limited further expands Krsnaa's opportunities in the fields of oncology and cardiology, allowing us to provide a comprehensive range of services in both radiology and pathology.

Currently, Krsnaa Diagnostics is well-positioned to deploy 21 CT scan units, 24 MRI machines, establish 1 lab, and set up 731 collection centers, all under various contractual agreements. These recent contract wins highlight the exceptional capabilities of our in-house teams, showcasing their proficiency in navigating the complex bidding process, meeting all requirements, and successfully securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, laying a strong foundation for sustainable, long-term growth.”

\*\*\*

## About Krsnaa Diagnostics:

Krsnaa Diagnostics Ltd. is India's fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 15 states and 3 Union Territories with 4,000+ centres across the country. Our mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and our commitment towards the same is what defines and differentiates us. We deliver clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for our patients in any corner of the country. With the most advanced technology in place, equipped with an advanced cloud based PACS workflow capable of rapid deployment and easy integration into flexible operational needs, accurate reports are delivered from well-qualified Radiologists and Pathologists from across the globe. We offer exceptional service with prompt turnaround of diagnostic reports, easy access to consultation with our team of diagnostic specialists, and the ability to handle diagnostic report needs. We provide world class healthcare diagnostics services at affordable rates with the approach of "Let's Do Good...".

## For further information, please contact

### Vivek Jain

Head - Investor Relation

Krsnaa Diagnostics Ltd.

+91 74107 00645

[head.investor@krsnaa.in](mailto:head.investor@krsnaa.in)

## Safe Harbour

*This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Krsnaa Diagnostics Ltd and its subsidiaries/associates ("Krsnaa Diagnostics"). These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Krsnaa Diagnostics, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.*